maintenance immunotherapy

Preclinical

maintenance immunotherapy is one of 3 therapeutic programs targeting Esophageal Squamous Cell Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Esophageal Squamous Cell CancerNot yet recruiting

Esophageal Squamous Cell CancerPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Esophageal Squamous Cell Cancer

#DrugCompanyPhaseTrials

Chemotherapy Followed Dendritic Cells

SShanghai Chest Hospital

Phase 2

1 2

maintenance immunotherapy

RRenJi Hospital

Preclinical

1 3

Induction Chemo-Immunotherapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalNot yet recruiting

Esophageal Squamous Cell Cancer

NCT07769866

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Cancer1 trial

Retlirafusp Alfa Combined With Definitive Concurrent Chemoradiotherapy in Local Advanced Unresectable Esophageal Squamous Cell Cancer

Not yet recruiting·RRenJi Hospital·Preclinical·NCT07769866·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for maintenance immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for maintenance immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — RenJi Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: RRenJi Hospital

maintenance immunotherapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Esophageal Squamous Cell Cancer1 trial

References

Drug Info

Quick Facts

Related News